# Safety and Food Effect on Single-Dose Bioavailability of F-02-2-Na in Healthy Adult Subjects

> **NCT07346027** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Hyperuricemia With or Without Gout

## Interventions

- **DRUG:** Fasting administration of F-02-2-Na (50mg) - Fed administration of F-02-2-Na (50mg)
- **DRUG:** Fed administration of F-02-2-Na (50mg) - Fasting administration of F-02-2-Na (50mg)

## Key facts

- **NCT ID:** NCT07346027
- **Lead sponsor:** Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07346027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07346027, "Safety and Food Effect on Single-Dose Bioavailability of F-02-2-Na in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07346027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*